Equity Rights Offering	3 Months Ended
Mar. 31, 2024
Warrants and Rights Note Disclosure [Abstract]
Equity Rights Offering	Note 9 – Equity Rights Offering In September 2020, the Corporation completed an equity-rights offering, issuing 5,507,889 shares of its common stock and 12,339,256 Series A warrants to existing shareholders. The shares of common stock and warrants are classified as equity instruments in the condensed consolidated statements of shareholders’ equity. Each Series A warrant provides the holder with the right to purchase 0.4464 shares of common stock at an exercise price of $2.5668, or $5.75 per whole share of common stock, and expires on August 1, 2025. For the three months ended March 31, 2024 and 2023, respectively, the Corporation received no proceeds from shareholders from the exercise of Series A warrants.

Equity Rights Offering

3 Months Ended

Mar. 31, 2024

Warrants and Rights Note Disclosure [Abstract]

Note 9 – Equity Rights Offering

In September 2020, the Corporation completed an equity-rights offering, issuing 5,507,889 shares of its common stock and 12,339,256 Series A warrants to existing shareholders. The shares of common stock and warrants are classified as equity instruments in the condensed consolidated statements of shareholders’ equity. Each Series A warrant provides the holder with the right to purchase 0.4464 shares of common stock at an exercise price of $2.5668, or $5.75 per whole share of common stock, and expires on August 1, 2025. For the three months ended March 31, 2024 and 2023, respectively, the Corporation received no proceeds from shareholders from the exercise of Series A warrants.